Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Amminger, GP, Nelson, B, Markulev, C, Yuen, HP, Schäfer, MR, Berger, M, Mossaheb, N, Schlögelhofer, M, Smesny, S, Hickie, IB, Berger, GE, Chen, EYH, de Haan, L, Nieman, DH, Nordentoft, M, Riecher-Rössler, A, Verma, S, Thompson, A, Yung, AR & McGorry, PD 2020, 'The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis' Biological Psychiatry, bind 87, nr. 3, s. 243-252. https://doi.org/10.1016/j.biopsych.2019.08.030

APA

CBE

Amminger GP, Nelson B, Markulev C, Yuen HP, Schäfer MR, Berger M, Mossaheb N, Schlögelhofer M, Smesny S, Hickie IB, Berger GE, Chen EYH, de Haan L, Nieman DH, Nordentoft M, Riecher-Rössler A, Verma S, Thompson A, Yung AR, McGorry PD. 2020. The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis. Biological Psychiatry. 87(3):243-252. https://doi.org/10.1016/j.biopsych.2019.08.030

MLA

Vancouver

Author

Amminger, G Paul ; Nelson, Barnaby ; Markulev, Connie ; Yuen, Hok Pan ; Schäfer, Miriam R ; Berger, Maximus ; Mossaheb, Nilufar ; Schlögelhofer, Monika ; Smesny, Stephan ; Hickie, Ian B ; Berger, Gregor E ; Chen, Eric Y H ; de Haan, Lieuwe ; Nieman, Dorien H ; Nordentoft, Merete ; Riecher-Rössler, Anita ; Verma, Swapna ; Thompson, Andrew ; Yung, Alison Ruth ; McGorry, Patrick D. / The NEURAPRO Biomarker Analysis : Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis. I: Biological Psychiatry. 2020 ; Bind 87, Nr. 3. s. 243-252.

Bibtex

@article{3aec0422e6e145f3bc9e8518063e1b6c,
title = "The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis",
abstract = "BACKGROUND: NEURAPRO was a multicenter, placebo-controlled trial of long-chain omega-3 polyunsaturated fatty acids (n-3 PUFAs) (fish oil) in 304 individuals at ultra-high risk for psychotic disorders. The study failed to show benefits of n-3 PUFAs over placebo. Although the randomized controlled trial design is placed at the top of the evidence hierarchy, this methodology has limitations in fish oil randomized controlled trials, as not only is the test agent present in the intervention group, but also n-3 fats are present in the diet and the body tissue of all participants.METHODS: Analysis of biomarker data (eicosapentaenoic acid [EPA], docosahexaenoic acid [DHA], n-3 index, EPA+DHA) collected as part of NEURAPRO was conducted on 218 participants with longitudinal biomarker data to determine if n-3 PUFAs measured in erythrocytes at baseline and month 6 predicted clinical outcomes.RESULTS: Increases of the n-3 index, EPA, and DHA predicted less severe psychopathology and better functioning at both follow-up time points. Higher baseline levels and increases of n-3 index also predicted overall clinical improvement at month 6 (n-3 index baseline: adjusted odds ratio [95{\%} confidence interval (CI)] = 1.79 [1.30-2.48]; n-3 PUFA increase: adjusted odds ratio [95{\%} CI] = 1.43 [1.16-1.76]) and at month 12 (n-3 index baseline: adjusted odds ratio [95{\%} CI] = 2.60 [1.71-3.97]; n-3 PUFA increase: adjusted odds ratio [95{\%} CI] = 1.36 [1.06-1.74]).CONCLUSIONS: These data suggest that n-3 PUFAs can exert therapeutic effects in ultra-high-risk individuals. This finding has implications for early intervention and treatment guidelines, as n-3 PUFA supplementation can easily and safely be used in a wide variety of settings, from primary care to specialist services.",
author = "Amminger, {G Paul} and Barnaby Nelson and Connie Markulev and Yuen, {Hok Pan} and Sch{\"a}fer, {Miriam R} and Maximus Berger and Nilufar Mossaheb and Monika Schl{\"o}gelhofer and Stephan Smesny and Hickie, {Ian B} and Berger, {Gregor E} and Chen, {Eric Y H} and {de Haan}, Lieuwe and Nieman, {Dorien H} and Merete Nordentoft and Anita Riecher-R{\"o}ssler and Swapna Verma and Andrew Thompson and Yung, {Alison Ruth} and McGorry, {Patrick D}",
note = "Copyright {\circledC} 2019 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.",
year = "2020",
month = "2",
day = "1",
doi = "10.1016/j.biopsych.2019.08.030",
language = "English",
volume = "87",
pages = "243--252",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier Inc",
number = "3",

}

RIS

TY - JOUR

T1 - The NEURAPRO Biomarker Analysis

T2 - Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis

AU - Amminger, G Paul

AU - Nelson, Barnaby

AU - Markulev, Connie

AU - Yuen, Hok Pan

AU - Schäfer, Miriam R

AU - Berger, Maximus

AU - Mossaheb, Nilufar

AU - Schlögelhofer, Monika

AU - Smesny, Stephan

AU - Hickie, Ian B

AU - Berger, Gregor E

AU - Chen, Eric Y H

AU - de Haan, Lieuwe

AU - Nieman, Dorien H

AU - Nordentoft, Merete

AU - Riecher-Rössler, Anita

AU - Verma, Swapna

AU - Thompson, Andrew

AU - Yung, Alison Ruth

AU - McGorry, Patrick D

N1 - Copyright © 2019 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

PY - 2020/2/1

Y1 - 2020/2/1

N2 - BACKGROUND: NEURAPRO was a multicenter, placebo-controlled trial of long-chain omega-3 polyunsaturated fatty acids (n-3 PUFAs) (fish oil) in 304 individuals at ultra-high risk for psychotic disorders. The study failed to show benefits of n-3 PUFAs over placebo. Although the randomized controlled trial design is placed at the top of the evidence hierarchy, this methodology has limitations in fish oil randomized controlled trials, as not only is the test agent present in the intervention group, but also n-3 fats are present in the diet and the body tissue of all participants.METHODS: Analysis of biomarker data (eicosapentaenoic acid [EPA], docosahexaenoic acid [DHA], n-3 index, EPA+DHA) collected as part of NEURAPRO was conducted on 218 participants with longitudinal biomarker data to determine if n-3 PUFAs measured in erythrocytes at baseline and month 6 predicted clinical outcomes.RESULTS: Increases of the n-3 index, EPA, and DHA predicted less severe psychopathology and better functioning at both follow-up time points. Higher baseline levels and increases of n-3 index also predicted overall clinical improvement at month 6 (n-3 index baseline: adjusted odds ratio [95% confidence interval (CI)] = 1.79 [1.30-2.48]; n-3 PUFA increase: adjusted odds ratio [95% CI] = 1.43 [1.16-1.76]) and at month 12 (n-3 index baseline: adjusted odds ratio [95% CI] = 2.60 [1.71-3.97]; n-3 PUFA increase: adjusted odds ratio [95% CI] = 1.36 [1.06-1.74]).CONCLUSIONS: These data suggest that n-3 PUFAs can exert therapeutic effects in ultra-high-risk individuals. This finding has implications for early intervention and treatment guidelines, as n-3 PUFA supplementation can easily and safely be used in a wide variety of settings, from primary care to specialist services.

AB - BACKGROUND: NEURAPRO was a multicenter, placebo-controlled trial of long-chain omega-3 polyunsaturated fatty acids (n-3 PUFAs) (fish oil) in 304 individuals at ultra-high risk for psychotic disorders. The study failed to show benefits of n-3 PUFAs over placebo. Although the randomized controlled trial design is placed at the top of the evidence hierarchy, this methodology has limitations in fish oil randomized controlled trials, as not only is the test agent present in the intervention group, but also n-3 fats are present in the diet and the body tissue of all participants.METHODS: Analysis of biomarker data (eicosapentaenoic acid [EPA], docosahexaenoic acid [DHA], n-3 index, EPA+DHA) collected as part of NEURAPRO was conducted on 218 participants with longitudinal biomarker data to determine if n-3 PUFAs measured in erythrocytes at baseline and month 6 predicted clinical outcomes.RESULTS: Increases of the n-3 index, EPA, and DHA predicted less severe psychopathology and better functioning at both follow-up time points. Higher baseline levels and increases of n-3 index also predicted overall clinical improvement at month 6 (n-3 index baseline: adjusted odds ratio [95% confidence interval (CI)] = 1.79 [1.30-2.48]; n-3 PUFA increase: adjusted odds ratio [95% CI] = 1.43 [1.16-1.76]) and at month 12 (n-3 index baseline: adjusted odds ratio [95% CI] = 2.60 [1.71-3.97]; n-3 PUFA increase: adjusted odds ratio [95% CI] = 1.36 [1.06-1.74]).CONCLUSIONS: These data suggest that n-3 PUFAs can exert therapeutic effects in ultra-high-risk individuals. This finding has implications for early intervention and treatment guidelines, as n-3 PUFA supplementation can easily and safely be used in a wide variety of settings, from primary care to specialist services.

U2 - 10.1016/j.biopsych.2019.08.030

DO - 10.1016/j.biopsych.2019.08.030

M3 - Journal article

VL - 87

SP - 243

EP - 252

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 3

ER -

ID: 59203050